ABSTRACT
BACKGROUND: Celecoxib, an anti-inflammatory drug, combined therapies using antimicrobials and immune modulator drugs are being studied. OBJECTIVE: To assess whether Celecoxib has direct in vitro antifungal effect against the Paracoccidioides brasiliensis, the causative agent of Paracoccidioidomycosis-(PCM) and also if it improves the in vivo activity of neutrophils-(PMN) in an experimental murine subcutaneous-(air pouch) model of the disease. METHODS: The antifungal activity of Celecoxib(6 mg/mL) on P. brasiliensis-(Pb18) was evaluated using the microdilution technique. Splenocytes co-cultured with Pb18 and treated with Celecoxib(6 mg/mL) were co-cultured for 24, 48 and 72-hours. Swiss mice were inoculated with Pb18 and treated with Celecoxib(6 mg/kg) in the subcutaneous air pouch. Neutrophils were collected from the air pouch. Mitochondrial activity, reactive oxygen production, catalase, peroxidase, cytokines and chemokines, nitrogen species, total protein, microbicidal activity of PMNs and viable Pb18 cells numbers were analyzed. RESULTS: Celecoxib had no cytotoxic effect on splenocytes co-cultured with Pb18, but had a marked direct antifungal effect, inhibiting fungal growth both in vitro and in vivo. Celecoxib interaction with immune system cells in the air pouch, it leads to activation of PMNs, as confirmed by several parameters (mitochondrial activity, reactive oxygen species, peroxidase, KC and IL-6 increase, killing constant and phagocytosis). Celecoxib was able to reduce IL-4, IL-10 and IL-12 cytokine production. The number of recovered viable Pb18 decreased dramatically. CONCLUSIONS: This is the first report of the direct antifungal activity of Celecoxib against P. brasiliensis. The use of Celecoxib opens a new possibility for future treatment of PCM.
Subject(s)
Antifungal Agents , Celecoxib , Neutrophils , Paracoccidioides , Paracoccidioidomycosis , Animals , Paracoccidioides/drug effects , Paracoccidioides/immunology , Mice , Celecoxib/pharmacology , Neutrophils/drug effects , Neutrophils/immunology , Paracoccidioidomycosis/drug therapy , Paracoccidioidomycosis/immunology , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Cytokines/metabolism , Cells, Cultured , Male , Spleen/immunology , Spleen/cytology , Spleen/drug effects , Disease Models, Animal , Reactive Oxygen Species/metabolismABSTRACT
BACKGROUND: Influenza A virus (IAV) causes respiratory disease in pigs and is a major concern for public health. Vaccination of pigs is the most successful measure to mitigate the impact of the disease in the herds. Influenza-based virosome is an effective immunomodulating carrier that replicates the natural antigen presentation pathway and has tolerability profile due to their purity and biocompatibility. METHODS: This study aimed to develop a polyvalent virosome influenza vaccine containing the hemagglutinin and neuraminidase proteins derived from the swine IAVs (swIAVs) H1N1, H1N2 and H3N2 subtypes, and to investigate its effectiveness in mice as a potential vaccine for swine. Mice were immunized with two vaccine doses (1 and 15 days), intramuscularly and intranasally. At 21 days and eight months later after the second vaccine dose, mice were euthanized. The humoral and cellular immune responses in mice vaccinated intranasally or intramuscularly with a polyvalent influenza virosomal vaccine were investigated. RESULTS: Only intramuscular vaccination induced high hemagglutination inhibition (HI) titers. Seroconversion and seroprotection (> 4-fold rise in HI antibody titers, reaching a titer of ≥ 1:40) were achieved in 80% of mice (intramuscularly vaccinated group) at 21 days after booster immunization. Virus-neutralizing antibody titers against IAV were detected at 8 months after vaccination, indicating long-lasting immunity. Overall, mice immunized with the virosome displayed greater ability for B, effector-T and memory-T cells from the spleen to respond to H1N1, H1N2 and H3N2 antigens. CONCLUSIONS: All findings showed an efficient immune response against IAVs in mice vaccinated with a polyvalent virosome-based influenza vaccine.
Subject(s)
Influenza Vaccines , Influenza, Human , Vaccines, Virosome , Bronchoalveolar Lavage , Influenza A Virus, H1N1 Subtype , Influenza A Virus, H1N2 Subtype , Influenza A Virus, H3N2 Subtype , Influenza Vaccines/administration & dosage , Influenza Vaccines/immunology , Influenza, Human/immunology , Spleen/cytology , Spleen/immunology , Vaccines, Combined/administration & dosage , Vaccines, Virosome/administration & dosage , Vaccines, Virosome/immunology , Virosomes/ultrastructure , Humans , Animals , MiceABSTRACT
Pregnancy is a common immunization event, but the molecular mechanisms and immunological consequences provoked by pregnancy remain largely unknown. We used mouse models and human transplant registry data to reveal that pregnancy induced exhausted CD8 T cells (Preg-TEX), which associated with prolonged allograft survival. Maternal CD8 T cells shared features of exhaustion with CD8 T cells from cancer and chronic infection, including transcriptional down-regulation of ribosomal proteins and up-regulation of TOX and inhibitory receptors. Similar to other models of T cell exhaustion, NFAT-dependent elements of the exhaustion program were induced by fetal antigen in pregnancy, whereas NFAT-independent elements did not require fetal antigen. Despite using conserved molecular circuitry, Preg-TEX cells differed from TEX cells in chronic viral infection with respect to magnitude and dependency of T cell hypofunction on NFAT-independent signals. Altogether, these data reveal the molecular mechanisms and clinical consequences of maternal CD8 T cell hypofunction and identify pregnancy as a previously unappreciated context in which T cell exhaustion may occur.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Gene Expression Profiling/methods , Lymphocyte Activation/immunology , NFATC Transcription Factors/immunology , Adoptive Transfer , Animals , Antigens/immunology , CD8-Positive T-Lymphocytes/metabolism , Chlorocebus aethiops , Female , Homeodomain Proteins/genetics , Homeodomain Proteins/immunology , Homeodomain Proteins/metabolism , Humans , Kaplan-Meier Estimate , Lymphocyte Activation/genetics , Lymphocytic Choriomeningitis/immunology , Lymphocytic Choriomeningitis/virology , Lymphocytic choriomeningitis virus/immunology , Lymphocytic choriomeningitis virus/physiology , Mice, Inbred C57BL , Mice, Transgenic , NFATC Transcription Factors/genetics , NFATC Transcription Factors/metabolism , Pregnancy , Programmed Cell Death 1 Receptor/genetics , Programmed Cell Death 1 Receptor/immunology , Programmed Cell Death 1 Receptor/metabolism , Skin Transplantation , Spleen/cytology , Spleen/immunology , Spleen/metabolism , Vero CellsABSTRACT
Hypoxia, angiogenesis, and immunosuppression have been proposed to be interrelated events that fuel tumor progression and impair the clinical effectiveness of anti-tumor therapies. Here we present new mechanistic data highlighting the role of hypoxia in fine-tuning CD8 T cell exhaustion in vitro, in an attempt to reconcile seemingly opposite evidence regarding the impact of hypoxia on functional features of exhausted CD8 T cells. Focusing on the recently characterized terminally-differentiated and progenitor exhausted CD8 T cells, we found that both hypoxia and its regulated mediator, vascular endothelial growth factor (VEGF)-A, promote the differentiation of PD-1+ TIM-3+ CXCR5+ terminally exhausted-like CD8 T cells at the expense of PD-1+ TIM-3- progenitor-like subsets without affecting tumor necrosis factor (TNF)-α and interferon (IFN)-γ production or granzyme B (GZMB) expression by these subpopulations. Interestingly, hypoxia accentuated the proangiogenic secretory profile in exhausted CD8 T cells. VEGF-A was the main factor differentially secreted by exhausted CD8 T cells under hypoxic conditions. In this sense, we found that VEGF-A contributes to generation of terminally exhausted CD8 T cells during in vitro differentiation. Altogether, our findings highlight the reciprocal regulation between hypoxia, angiogenesis, and immunosuppression, providing a rational basis to optimize synergistic combinations of antiangiogenic and immunotherapeutic strategies, with the overarching goal of improving the efficacy of these treatments.
Subject(s)
CD8-Positive T-Lymphocytes/physiology , Cell Differentiation/immunology , Hypoxia , Animals , CD8-Positive T-Lymphocytes/drug effects , Cell Differentiation/drug effects , Humans , Immune Tolerance , Mice, Inbred C57BL , Spleen/cytology , Vascular Endothelial Growth Factor A/immunology , Vascular Endothelial Growth Factor A/pharmacologyABSTRACT
BACKGROUND: In recent years, there has been great interest in developing molecular adjuvants based on antisense oligonucleotides (ASOs) targeting immunosuppressor pathways with inhibitory effects on regulatory T cells (Tregs) to improve immunogenicity and vaccine efficacy. We aim to evaluate the immunostimulating effect of 2'OMe phosphorothioated Foxp3-targeted ASO in an antifungal adjuvanted recombinant vaccine. METHODS: The uptake kinetics of Foxp3 ASO, its cytotoxicity and its ability to deplete Tregs were evaluated in murine splenocytes in vitro. Groups of mice were vaccinated with recombinant enolase (Eno) of Sporothix schenckii in Montanide Gel 01 adjuvant alone or in combination with either 1 µg or 8 µg of Foxp3 ASO. The titers of antigen-specific antibody in serum samples from vaccinated mice (male C57BL/6) were determined by ELISA (enzyme-linked immunosorbent assay). Cultured splenocytes from each group were activated in vitro with Eno and the levels of IFN-γ and IL-12 were also measured by ELISA. The results showed that the anti-Eno antibody titer was significantly higher upon addition of 8 µM Foxp3 ASO in the vaccine formulation compared to the standard vaccine without ASO. In vitro and in vivo experiments suggest that Foxp3 ASO enhances specific immune responses by means of Treg depletion during vaccination. CONCLUSION: Foxp3 ASO significantly enhances immune responses against co-delivered adjuvanted recombinant Eno vaccine and it has the potential to improve vaccine immunogenicity.
Subject(s)
Forkhead Transcription Factors/genetics , Gene Silencing , Immunogenicity, Vaccine , Oligonucleotides, Antisense/chemistry , Sporothrix/immunology , Vaccines, Synthetic/immunology , Adjuvants, Immunologic/administration & dosage , Adjuvants, Pharmaceutic , Animals , Immune System , Interferon-gamma/metabolism , Interleukin-12 Subunit p35/metabolism , Kinetics , Male , Mice , Mice, Inbred C57BL , Spleen/cytology , T-Lymphocytes, Regulatory/metabolismABSTRACT
Introduction: Arsenic is an environmental toxic present worldwide. In men and animals, various organs and tissues are targets of its deleterious effects including those of the immune system. Objective: To determine acute arsenic toxicity in tissues and target cells of Balb/c mice using an in vivo methodology. Materials and methods: We injected Balb/c mice intraperitoneally with 9.5 or 19 mg/kg of sodium arsenite (NaAsO2), or an equivalent volume of physiological solution as a control (with 3 per experimental group). After 30 minutes, the animals were sacrificed to obtain spleen, thymus, liver, kidneys, and blood. We determined arsenic, polyphenols, and iron concentrations in each sample and we evaluated the oxidative markers (peroxides, advanced products of protein oxidation, and free sulfhydryl groups). In splenocytes from the spleen, cell viability and mitochondrial potential were also determined. Results: The exposure to an acute dose of NaAsO2 reduced the mitochondrial function of splenocytes, which resulted in cell death. Simultaneously, the confirmed presence of arsenic in spleen samples and the resulting cytotoxicity occurred with a decrease in polyphenols, free sulfhydryl groups, and an alteration in the content and distribution of iron, but did not increase the production of peroxides. Conclusion: These findings provide scientific evidence about changes occurring in biomarkers involved in the immunotoxicity of arsenic and offer a methodology for testing possible treatments against the deleterious action of this compound on the immune system.
Introducción. El arsénico es un tóxico ambiental ampliamente diseminado en todo el mundo. En hombres y animales, diversos órganos y tejidos son blancos de sus efectos deletéreos, entre ellos, el los del sistema inmunológico. Objetivo. Determinar la intoxicación aguda por arsénico en tejidos y células diana de ratones Balb/c in vivo. Materiales y métodos. Se aplicó una inyección intraperitoneal de 9,5 o 19 mg/kg de arsenito de sodio (NaAsO2) o un volumen equivalente de solución fisiológica como control, en ratones Balb/c con 3 por cada grupo experimental. Tras media hora, los animales fueron sacrificados y se extrajeron bazos, timos, hígados, riñones y sangre. En cada muestra, se determinó la concentración de arsénico, polifenoles y hierro, y también, se evaluaron marcadores oxidativos, como peróxidos, productos avanzados de oxidación proteica y grupos sulfhidrilos libres. En los esplenocitos obtenidos del bazo, se determinaron la viabilidad celular y el potencial mitocondrial. Resultados. La dosis aguda inyectada de NaAsO2 redujo la función mitocondrial de los esplenocitos, lo que derivó en muerte celular. La presencia confirmada de arsénico en las muestras de bazo y la citotoxicidad resultante, produjeron disminución de los polifenoles y de los grupos sulfhidrilos libres, y alteraron el contenido y la distribución del hierro, pero no se aumentó la producción de peróxidos. Conclusión. Estos hallazgos aportan evidencia científica sobre los cambios en biomarcadores involucrados en la inmunotoxicidad del arsénico y ofrecen, además, una metodología para ensayar potenciales tratamientos frente a la acción deletérea de este compuesto en el sistema inmunológico.
Subject(s)
Arsenic/toxicity , Spleen/drug effects , Animals , Cells, Cultured , Male , Mice , Mice, Inbred BALB C , Spleen/cytologyABSTRACT
Active immunotherapy against cancer is based on immune system stimulation, triggering efficient and long-lasting antigen-specific immune responses. Immunization strategies using whole dead cells from tumor tissue, containing specific antigens inside, have become a promising approach, providing efficient lymphocyte activation through dendritic cells (DCs). In this work, we generate whole dead tumor cells from CT26, E.G7, and EL4 live tumor cells as antigen sources, which termed immunogenic cell bodies (ICBs), generated by a simple and cost-efficient starvation-protocol, in order to determine whether are capable of inducing a transversal anticancer response regardless of the tumor type, in a similar way to what we describe previously with B16 melanoma. We evaluated the anticancer effects of immunization with doses of ICBs in syngeneic murine tumor models. Our results showed that mice's immunization with ICBs-E.G7 and ICBs-CT26 generate 18% and 25% of tumor-free animals, respectively. On the other hand, all carrying tumor-animals and immunized with ICBs, including ICBs-EL4, showed a significant delay in their growth compared to not immunized animals. These effects relate to DCs maturation, cytokine production, increase in CD4+T-bet+ and CD4+ROR-γt+ population, and decrease of T regulatory lymphocytes in the spleen. Altogether, our data suggest that whole dead tumor cell-based cancer immunotherapy generated by a simple starvation protocol is a promising way to develop complementary, innovative, and affordable antitumor therapies in a broad spectrum of tumors.
Subject(s)
Antigens, Neoplasm , Colonic Neoplasms/immunology , Immunotherapy , Lymphoma/immunology , Tumor Cells, Cultured/immunology , Animals , Antigens, Neoplasm/immunology , Antigens, Neoplasm/metabolism , Autophagy , Cell Culture Techniques , Cytokines/metabolism , Female , Male , Mice , Mice, Inbred C57BL , Spleen/cytologyABSTRACT
Although acute stress generally exerts positive effects on the immune system, chronic stress typically causes immunosuppression via the hypothalamic-pituitary-adrenal (HPA) axis. In this study, the effects of capsaicin (1.28 mg/kg intraperitoneally [i.p.] for 7 days) on immune parameters were evaluated under conditions of chronic stress. Capsaicin treatment significantly increased the immune response as evaluated by the delayed-type hypersensitivity (DTH) reaction to dinitrofluorobenzene (DNFB) and splenocyte proliferation assays- It also is able to rescue the splenocytes of the apoptosis induced by stress. The capsaicin treatment increased the production of Th1 cytokines and decreased the production of Th2 cytokines and TGF-ß1 in the plasma and culture supernatants of immunosuppressed mice, which is associated with the modulation of Th2 induced by stress cells. Moreover, the production of corticosterone significantly decreased in capsaicin-treated animals as compared to control groups. The capsaicin treatment further attenuated the immunosuppression induced by the corticosterone treatment (40 mg/kg i.p. for 7 days), albeit less potently, as exhibited in the DTH response. Intriguingly, the capsaicin treatment decreased the induction of IL-10, IL-4, and TGF-ß1 through high doses of corticosterone, indicating direct cellular immunomodulation. These results show, that capsaicin is able to modulate chronic stress-induced immunosuppression, mediating corticosterone released inhibition, but also, that capsaicin significantly modulates the pharmacological action of corticosterone in vivo.
Subject(s)
Capsaicin/pharmacology , Immune Tolerance/drug effects , Immunologic Factors/pharmacology , Stress, Physiological/drug effects , Animals , Cell Proliferation/drug effects , Corticosterone/pharmacology , Cytokines/blood , Cytokines/immunology , Dinitrofluorobenzene , Hypersensitivity, Delayed/immunology , Male , Mice, Inbred BALB C , Spleen/cytology , Stress, Physiological/immunology , Transforming Growth Factor beta1/blood , Transforming Growth Factor beta1/immunologyABSTRACT
BACKGROUND: Protease inhibitors have been isolated from plants and present several biological activities, including immunomodulatory action. OBJECTIVE: This work aimed to evaluate a Moringa oleifera flower trypsin inhibitor (MoFTI) for acute toxicity in mice, hemolytic activity on mice erythrocytes and immunomodulatory effects on mice splenocytes. METHODS: The acute toxicity was evaluated using Swiss female mice that received a single dose of the vehicle control or MoFTI (300 mg/kg, i.p.). Behavioral alterations were observed 15-240 min after administration, and survival, weight gain, and water and food consumption were analyzed daily. Organ weights and hematological parameters were analyzed after 14 days. Hemolytic activity of MoFTI was tested using Swiss female mice erythrocytes. Splenocytes obtained from BALB/c mice were cultured in the absence or presence of MoFTI for the evaluation of cell viability and proliferation. Mitochondrial membrane potential (Δψm) and reactive oxygen species (ROS) levels were also determined. Furthermore, the culture supernatants were analyzed for the presence of cytokines and nitric oxide (NO). RESULTS: MoFTI did not cause death or any adverse effects on the mice except for abdominal contortions at 15-30 min after administration. MoFTI did not exhibit a significant hemolytic effect. In addition, MoFTI did not induce apoptosis or necrosis in splenocytes and had no effect on cell proliferation. Increases in cytosolic and mitochondrial ROS release, as well as Δψm reduction, were observed in MoFTI-treated cells. MoFTI was observed to induce TNF-α, IFN-γ, IL-6, IL-10, and NO release. CONCLUSION: These results contribute to the ongoing evaluation of the antitumor potential of MoFTI and its effects on other immunological targets.
Subject(s)
Moringa oleifera/enzymology , Plant Proteins , Trypsin Inhibitors , Animals , Behavior, Animal/drug effects , Cell Proliferation/drug effects , Cells, Cultured , Female , Flowers/chemistry , Hemolysis/drug effects , Mice , Mice, Inbred BALB C , Plant Proteins/chemistry , Plant Proteins/metabolism , Plant Proteins/pharmacology , Plant Proteins/toxicity , Spleen/cytology , Toxicity Tests, Acute , Trypsin Inhibitors/chemistry , Trypsin Inhibitors/metabolism , Trypsin Inhibitors/pharmacology , Trypsin Inhibitors/toxicityABSTRACT
Daily oscillation of the immune system follows the central biological clock outputs control such as melatonin produced by the pineal gland. Despite the literature showing that melatonin is also synthesized by macrophages and T lymphocytes, no information is available regarding the temporal profile of the melatonergic system of immune cells and organs in steady-state. Here, the expression of the enzymes arylalkylamine-N-acetyltransferase (AA-NAT), its phosphorylated form (P-AA-NAT) and acetylserotonin-O-methyltransferase (ASMT) were evaluated in phagocytes and T cells of the bone marrow (BM) and spleen. We also determined how the melatonergic system of these cells is modulated by LPS and the cytokine IL-10. The expression of the melatonergic enzymes showed daily rhythms in BM and spleen cells. Melatonin rhythm in the BM, but not in the spleen, follows P-AA-NAT daily variation. In BM cells, LPS and IL10 induced an increase in melatonin levels associated with the increased expressions of P-AA-NAT and ASMT. In spleen cells, LPS induced an increase in the expression of P-AA-NAT but not of melatonin. Conversely, IL10 induced a significant increase in melatonin production associated with increased AA-NAT/P-AA-NAT expressions. In conclusion, BM and spleen cells present different profiles of circadian production of local melatonin and responses to immune signals.
Subject(s)
Bone Marrow Cells/immunology , Circadian Rhythm/physiology , Interleukin-10/pharmacology , Lipopolysaccharides/pharmacology , Melatonin/biosynthesis , Spleen/cytology , Spleen/immunology , Acetylserotonin O-Methyltransferase/genetics , Acetylserotonin O-Methyltransferase/metabolism , Animals , Arylalkylamine N-Acetyltransferase/genetics , Arylalkylamine N-Acetyltransferase/metabolism , Bone Marrow Cells/drug effects , Bone Marrow Cells/metabolism , Cells, Cultured , Gene Expression/drug effects , Male , Phagocytes/immunology , Phagocytes/metabolism , Rats, Wistar , Spleen/drug effects , Spleen/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolismABSTRACT
BACKGROUND: T cell therapy for cancer involves genetic introduction of a target-binding feature into autologous T cells, ex vivo expansion and single large bolus administration back to the patient. These reprogrammed T cells can be highly effective in killing cells, but tumor heterogeneity results in regrowth of cells that do not sufficiently express the single antigen being targeted. We describe a cell-based therapy that simultaneously targets multiple tumor-specific antigens. METHODS: High-affinity polyclonal rabbit antibodies were generated against nine different surface-related tumor-specific mutations on B16F10 cells. Unsorted splenic effector cells from syngeneic mice were incubated with a cocktail of the nine anti-B16F10 antibodies. These 'armed' effector cells were used to treat mice previously inoculated with B16F10 melanoma cells. RESULTS: The cocktail of nine antibodies resulted in dense homogeneous binding to histological sections of B16F10 cells. Five treatments with the armed effector cells and PD1 inhibition inhibited tumor growth and improved survival. Shortening the interval of the five treatments from every three days to every day increased survival. Arming effector cells with the four antibodies showing best binding to B16F10 cells even further increased survival. CONCLUSIONS: This study demonstrates that ex vivo arming a mixed population of immune effector cells with antibodies targeting multiple tumor-specific mutated proteins in conjunction with PD1 inhibition delayed tumor growth and prolonged survival in mice inoculated with an aggressive melanoma. A remarkably low total antibody dose of less than 5 µg was sufficient to accomplish tumor inhibition. Scaling up to clinical level may be feasible.
Subject(s)
Antibodies, Neoplasm/therapeutic use , Antigens, Neoplasm/immunology , Immunotherapy, Adoptive/methods , Leukocytes/immunology , Melanoma, Experimental/therapy , Skin Neoplasms/therapy , Tumor Burden , Animals , Antigens, Neoplasm/genetics , Melanoma, Experimental/immunology , Melanoma, Experimental/pathology , Mice , Mutant Proteins/genetics , Mutant Proteins/immunology , Mutation , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Skin Neoplasms/immunology , Skin Neoplasms/pathology , Spleen/cytology , Survival RateABSTRACT
In contrast to steady-state erythropoiesis, which generates new erythrocytes at a constant rate, stress erythropoiesis rapidly produces a large bolus of new erythrocytes in response to anemic stress. In this study, we illustrate that Yes-associated protein (Yap1) promotes the rapid expansion of a transit-amplifying population of stress erythroid progenitors in vivo and in vitro. Yap1-mutated erythroid progenitors failed to proliferate in the spleen after transplantation into lethally irradiated recipient mice. Additionally, loss of Yap1 impaired the growth of actively proliferating erythroid progenitors in vitro. This role in proliferation is supported by gene expression profiles showing that transiently amplifying stress erythroid progenitors express high levels of genes associated with Yap1 activity and genes induced by Yap1. Furthermore, Yap1 promotes the proliferation of stress erythroid progenitors in part by regulating the expression of key glutamine-metabolizing enzymes. Thus, Yap1 acts as an erythroid regulator that coordinates the metabolic status with the proliferation of erythroid progenitors to promote stress erythropoiesis.
Subject(s)
Adaptor Proteins, Signal Transducing/physiology , Cell Cycle Proteins/physiology , Erythroid Precursor Cells/physiology , Erythropoiesis/physiology , Regeneration/physiology , Adaptor Proteins, Signal Transducing/genetics , Alleles , Animals , Cell Division , Cells, Cultured , Enzyme Induction , Erythroid Precursor Cells/cytology , Gene Deletion , Gene Expression Profiling , Gene Expression Regulation , Mice , Mice, Inbred C57BL , RNA, Messenger/biosynthesis , Radiation Chimera , Radiation Tolerance , Recombinant Proteins/metabolism , Spleen/cytology , Stress, Physiological/genetics , Transcription Factors/genetics , YAP-Signaling ProteinsABSTRACT
Conventional dendritic cells (cDCs) cannot be infected by porcine reproductive and respiratory syndrome virus (PRRSV) but respond to infection via cytokine production, indicating a possible role in initiation/regulation of the immune response against PRRSV. In this work, we evaluated the responses of splenic and blood cDCs, with DEC205+CADM1+CD172a+/- phenotype, as well as those of CD163+ cells against PRRSV and porcine epidemic diarrhea virus (PEDV). Both populations were incubated in the presence of PRRSV or PEDV with and without naïve CD3+ T cells, and cytokine responses were evaluated by qPCR and ELISA. Our results showed that cDCs, but not CD163+ cells, produced IL-12 in response to PRRSV. PEDV did not induce IL-12 production. Cocultures of cDCs and autologous naïve CD3+ cells resulted in decreased IL-12 production and low expression of IFN-γ transcripts in response to PRRSV. Interestingly, cDCs increased the proliferation of naïve T cells in the presence of PRRSV compared with that achieved with monocytes and peripheral blood mononuclear cells (PBMCs). Cocultures of CD163+ cells induced IL-10 and IL-4 expression in the presence of PRRSV and PEDV, respectively. In conclusion, cDCs can selectively produce IL-12 in response to PRRSV but poorly participate in the activation of naïve T cells.
Subject(s)
Coronavirus Infections/veterinary , Dendritic Cells/immunology , Porcine Reproductive and Respiratory Syndrome/immunology , T-Lymphocytes , Animals , Antigens, CD/blood , Antigens, Differentiation, Myelomonocytic/blood , Cell Adhesion Molecule-1/blood , Coronavirus Infections/immunology , Cytokines/blood , Dendritic Cells/virology , Interleukin-10/blood , Interleukin-12/blood , Interleukin-4/blood , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/virology , Monocytes/immunology , Monocytes/virology , Porcine epidemic diarrhea virus , Porcine respiratory and reproductive syndrome virus , Primary Cell Culture , Receptors, Cell Surface/blood , Spleen/cytology , Spleen/immunology , Spleen/virology , Swine , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/virology , T-Lymphocytes/immunology , T-Lymphocytes/virologyABSTRACT
BACKGROUND: Lectins have been studied in recent years due to their immunomodulatory activities. OBJECTIVE: We purified a lectin named OniL from tilapia fish (Oreochromis niloticus) and here we analyzed the cell proliferation and cytokine production in Balb/c mice splenocytes. METHODS: Cells were stimulated in vitro in 24, 48, 72 hours and 6 days with different concentrations of OniL and Con A. Evaluation of cell proliferation was performed through [3H]-thymidine incorporation, cytokines were investigated using ELISA assay and cell viability assay was performed by investigation of damage through signals of apoptosis and necrosis. RESULTS: OniL did not promote significant cell death, induced high mitogenic activity in relation to control and Con A and stimulated the cells to release high IL-2 and IL-6 cytokines. CONCLUSION: These findings suggest that, like Con A, OniL lectin can be used as a mitogenic agent in immunostimulatory assays.
Subject(s)
Cell Proliferation/drug effects , Mannose-Binding Lectins/pharmacology , Mitogens/pharmacology , Spleen/cytology , Animals , Cell Death , Cell Line , Cell Survival , Concanavalin A/pharmacology , Cytokines/biosynthesis , Male , Mice, Inbred BALB C , TilapiaABSTRACT
BACKGROUND: Adaptive immune cells, including CD4+CD69+ and CD4+CD25+FoxP3+ regulatory T (Treg) cells, are important for maintaining immunological tolerance. In human systemic lupus erythematosus (SLE), CD4+CD25+FoxP3+ Treg cells are reduced, whereas CD69 expression is increased, resulting in a homeostatic immune imbalance that may intensify autoreactive T cell activity. To analyze the mechanisms implicated in autotolerance failure, we evaluated CD4+CD69+ and CD4+CD25+FoxP3+ T cells and interleukin profiles in a pristane-induced SLE experimental model. METHODS: For lupus induction, 26 female Balb/c mice received a single intraperitoneal 0.5 ml dose of pristane, and 16 mice received the same dose of saline. Blood and spleen samples were collected from euthanized mice 90 and 120 days after pristane or saline inoculation. Mononuclear cells from peripheral blood (PBMC), peritoneal lavage (PL) and splenocytes were obtained by erythrocyte lysis and cryopreserved for further evaluation by flow cytometry using the GuavaEasyCyte TM HT. After thawing, cells were washed and stained with monoclonal antibodies against CD3, CD4, CD8, CD25, CD28, CD69, FoxP3, CD14 and Ly6C (BD Pharmingen TM). Interleukins were quantified using Multiplex® MAP. The Mann-Whitney test and the Pearson coefficient were used for statistical analysis, and p < 0.05 considered significant. RESULTS: Compared with the controls, SLE-induced animals presented increased numbers of CD4+CD69+ T cells in the blood on T90 and T120 (p = 0.022 and p = 0.008) and in the spleen on T120 (p = 0.049), but there were decreased numbers in the PL (p = 0.049) on T120. The percentage of Treg was lower in blood (p < 0.005 and p < 0.012) on T90 and T120, in spleen (p = 0.043) on T120 and in PL (p = 0.001) on T90. Increased numbers of CD4 + CD69+ T cells in the PL were positively associated with high IL-2 (p = 0.486) and IFN-γ (p = 0.017) levels, whereas reduced Treg cells in the blood were negatively correlated with TNFα levels (p = 0.043) and positively correlated with TGFß1 (p = 0.038). CONCLUSION: Increased numbers of CD4+CD69+ T cells and reduced numbers of CD4+CD25+FoxP3+ Treg cells with an altered interleukin profile suggests loss of autotolerance in pristane-induced lupus mice, which is similar to human lupus. Therefore, this model is useful in evaluating mechanisms of cellular activation, peripheral tolerance and homeostatic immune imbalance involved in human SLE.
Subject(s)
CD4-Positive T-Lymphocytes/cytology , Lupus Erythematosus, Systemic/immunology , Peritoneal Lavage , Spleen/cytology , T-Lymphocytes, Regulatory/cytology , Animals , Antigens, CD/analysis , Antigens, CD/immunology , Antigens, Differentiation, T-Lymphocyte/analysis , Antigens, Differentiation, T-Lymphocyte/immunology , Antigens, Ly/analysis , Antigens, Ly/immunology , CD28 Antigens/analysis , CD28 Antigens/immunology , CD4-Positive T-Lymphocytes/immunology , Female , Forkhead Transcription Factors/analysis , Forkhead Transcription Factors/immunology , Immunosuppressive Agents , Interleukin-2 Receptor alpha Subunit/analysis , Interleukin-2 Receptor alpha Subunit/immunology , Lectins, C-Type/analysis , Lectins, C-Type/immunology , Lipopolysaccharide Receptors/analysis , Lipopolysaccharide Receptors/immunology , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/chemically induced , Lymphocyte Count , Mice , Mice, Inbred BALB C , Spleen/immunology , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Regulatory/immunology , TerpenesABSTRACT
Gliotoxin (GTX) is the major and the most potent mycotoxin that is secreted by Aspergillus fumigatus, which is capable of injuring and killing microglial cells, astrocytes, and oligodendrocytes. During the last years, studies with patients and experimental models of multiple sclerosis (MS), which is an autoimmune disease of the central nervous system (CNS), suggested that fungal infections are among the possible initiators or aggravators of this pathology. The deleterious effect can occur through a direct interaction of the fungus with the CNS or by the toxin release from a non-neurological site. In the present work, we investigated the effect of GTX on experimental autoimmune encephalomyelitis (EAE) development. Female C57BL/6 mice were immunized with myelin oligodendrocyte glycoprotein and then intraperitoneally injected with three doses of GTX (1 mg/kg b.w., each) on days 4, 7, and 10. GTX aggravated clinical symptoms of the disease in a dose-dependent way and this outcome was concomitant with an increased neuroinflammation. CNS analyses revealed that GTX locally increased the relative expression of inflammatory genes and the cytokine production. Our results indicate that GTX administered in a non-neuronal site was able to increase neuroinflammation in EAE. Other mycotoxins could also be deleterious to many neurological diseases by similar mechanisms.
Subject(s)
Encephalomyelitis, Autoimmune, Experimental , Gliotoxin/toxicity , Animals , Aspergillus fumigatus , Cytokines/immunology , Encephalomyelitis, Autoimmune, Experimental/immunology , Encephalomyelitis, Autoimmune, Experimental/metabolism , Encephalomyelitis, Autoimmune, Experimental/pathology , Female , Mice, Inbred C57BL , Spinal Cord/drug effects , Spinal Cord/metabolism , Spinal Cord/pathology , Spleen/cytology , Spleen/drug effects , Spleen/immunologyABSTRACT
The ability of B lymphocytes to capture external antigens (Ag) and present them as peptide fragments, loaded on major histocompatibility complex (MHC) class II molecules, to CD4+ T cells is a crucial part of the adaptive immune response. This allows for T-B cooperation, a cellular communication that is required for B cells to develop into germinal centers (GC) and form mature high affinity antibody producing cells and to further develop B cell memory. MHC class II antigen presentation by B lymphocytes is a multistep process involving (1) Recognition and capture of external Ag by B lymphocytes through their B cell receptor (BCR), (2) Ag processing, which comprises the degradation of Ag in internal compartments within the B cell and loading of the corresponding peptide fragments on MHC class II molecules, and (3) Presentation of MHCII-peptide complexes to CD4+ T cells. Here, we describe how to study the biochemical and morphological changes that occur in B lymphocytes at these three major levels.
Subject(s)
Antigen Presentation/immunology , Antigens/metabolism , B-Lymphocytes/immunology , Histocompatibility Antigens Class II/immunology , Immobilized Proteins/metabolism , Animals , Cell Line , Lymphocyte Activation/immunology , Mice , Spleen/cytology , Synaptic Membranes/metabolismABSTRACT
Currently, the research of new natural compounds with biological potential demonstrates great ethnopharmacological importance. In this study, we evaluated the biological properties promoted by saline extract from Malpighia emarginata DC leaves, whose objective is to evaluate the antioxidant, antimicrobial and cytotoxicity potential. Phytochemical characterization was performed by UPLC-MS chromatography to identify the chemical compounds. For the antioxidant potential, DPPH, ATT and FRAP methods were used. The antibacterial and antifungal tests were performed evaluating the MIC50, MIC90, CMB and CMF parameters. Moreover, antibiofilm action was evaluated. Cytotoxicity and proliferation were performed using splenocytes from Balb/c mice and were evaluated by cytometry. We found a list of phenolic compounds among other bioactive compounds in the M. emarginata saline extract. In addition, higher antioxidant profile and antifungal activity against different strains of Candida spp. was promoted by the saline extract. Splenocytes showed greater cell viability (more than 90%) and showed higher proliferate index in 24 and 48 hours of incubation with the extract. Saline extract from Malpighia emarginata DC has potential action like antioxidant and antifungal agent without promote animal cell damage.
Subject(s)
Antifungal Agents/chemistry , Antioxidants/chemistry , Cell Proliferation/drug effects , Malpighiaceae/chemistry , Plant Extracts/chemistry , Plant Leaves/chemistry , Polyphenols/chemistry , Animals , Antifungal Agents/pharmacology , Antioxidants/pharmacology , Candida/drug effects , Cell Survival/drug effects , Chromatography, High Pressure Liquid/methods , Female , Flavonoids/chemistry , Mice, Inbred BALB C , Microbial Sensitivity Tests , Plant Extracts/pharmacology , Polyphenols/pharmacology , Reference Values , Spleen/cytology , Time FactorsABSTRACT
BACKGROUND: A recombinant BCG strain expressing the genetically detoxified S1 subunit of pertussis toxin 9K/129G (rBCG-S1PT), previously constructed by our research group, demonstrated the ability to develop high protection in mouse models of pertussis challenge which correlated with the induction of a Th1 immune response pattern. The Th1 immune response induced by rBCG-S1PT treatment was also confirmed in the murine orthotopic bladder cancer model, in which the intravesical instillation of rBCG-S1PT resulted in an improved antitumor effect. Based on these observations, we hypothesize that the reengineering of the S1PT expression in BCG could increase the efficiency of the protective Th1 immune response in order to develop a new alternative of immunotherapy in bladder cancer treatment. OBJECTIVES: To construct rBCG strains expressing S1PT from extrachromosomal (rBCG-S1PT) and integrative vectors (rBCG-Sli), or their combination, generating the bivalent strain (rBCG-S1+S1i), and to evaluate the respective immunogenicity of rBCG strains in mice. METHODS: Mycobacterial plasmids were constructed by cloning the s1pt gene under integrative and extrachromosomal vectors and used to transform BCG, individually or in combination. Antigen expression and localization were confirmed by Western blot. Mice were immunized with wild-type BCG or the rBCG strains, and cytokines quantification and flow cytometry analysis were performed in splenocytes culture stimulated with mycobacterial-specific proteins. FINDINGS: S1PT expression was confirmed in all rBCG strains. The extrachromosomal vector directs S1PT to the cell wall-associated fraction, while the integrative vector directs its expression mainly to the intracellular fraction. Higher levels of IFN-γ were observed in the splenocytes culture from the group immunized with rBCG-S1i in comparison to BCG or rBCG-S1PT. rBCG-S1+S1i showed higher levels of CD4+ IFN-γ + and double-positive CD4+ IFN-γ + TNF-α + T cells. CONCLUSIONS: rBCG-S1+S1i was able to express the two forms of S1PT and elicited higher induction of polyfunctional CD4+ T cells, indicating enhanced immunogenicity and suggesting its use as immunotherapy for bladder cancer.
Subject(s)
BCG Vaccine/immunology , CD4-Positive T-Lymphocytes/immunology , Immunity, Cellular , Mycobacterium bovis/physiology , Pertussis Toxin/metabolism , Protein Subunits/metabolism , Vaccines, Synthetic/immunology , Animals , Cytokines/biosynthesis , Cytokines/metabolism , Female , Immunization , Inflammation Mediators/metabolism , Mice, Inbred BALB C , Phenotype , Plasmids/metabolism , Spleen/cytologyABSTRACT
Autoreactive B cells that bind self-antigen with high avidity in the bone marrow undergo mechanisms of central tolerance that prevent their entry into the peripheral B cell population. These mechanisms are breached in many autoimmune patients, increasing their risk of B cell-mediated autoimmune diseases. Resolving the molecular pathways that can break central B cell tolerance could therefore provide avenues to diminish autoimmunity. Here, we show that B cell-intrinsic expression of a constitutively active form of PI3K-P110α by high-avidity autoreactive B cells of mice completely abrogates central B cell tolerance and further promotes these cells to escape from the bone marrow, differentiate in peripheral tissue, and undergo activation in response to self-antigen. Upon stimulation with T cell help factors, these B cells secrete antibodies in vitro but remain unable to secrete autoantibodies in vivo. Overall, our data demonstrate that activation of the PI3K pathway leads high-avidity autoreactive B cells to breach central, but not late, stages of peripheral tolerance.